Back to top

VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?

Read MoreHide Full Article

A month has gone by since the last earnings report for VIVUS, Inc. (VVUS - Free Report) . Shares have lost about 19.8% in that time frame, underperforming the market.

Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

VIVUS Loss Narrower than Expected, Revenues Up Y/Y

VIVUS reported a loss of $0.13 per share in the second quarter of 2017, which was wider than a loss of $0.12 in the year-ago period. However, the loss was in line with the Zacks Consensus Estimate.

However, quarterly revenues decreased 18.5% to $11.2 million from the year-ago period.

Quarter in Detail

Qsymia generated net product sales of $8.5 million, down 33.2% from the year-ago period due to reduction in Qsymia inventory by the wholesalers and change in revenue recognition methodology.

Supply and royalty revenues from Stendra/Spedra were $2.7 million, up 163.8% from the year-ago period due to an increase in supply revenues as a number of orders placed by commercialization partners in this quarter were better than the year-ago period.

General and administrative expense was $11.6 million, down 22.4% year over year mainly attributable to cost control initiatives undertaken by the company. Research and development expense decreased almost 7.5% to $1 million in the reported quarter due to cost savings efforts related to Qsymia regulatory requirements partially offset by costs incurred for development of tacrolimus

How Have Estimates Been Moving Since Then?

Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.

VIVUS, Inc. Price and Consensus


VIVUS, Inc. Price and Consensus | VIVUS, Inc. Quote

VGM Scores

Currently, the stock has a poor Growth Score of F, however its Momentum is doing a lot better with an A. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

The company's stock is suitable solely for momentum based on our styles scores.


The stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

VIVUS, Inc. (VVUS) - free report >>

More from Zacks Realtime BLOG

You May Like